Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events
NCT00346242
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Thalassemia
Interventions
DRUG:
Zoledronic Acid
Sponsor
Novartis Pharmaceuticals